...
首页> 外文期刊>The journal of obstetrics and gynaecology research >Expression and purification of the extracellular domain of the human follicle-stimulating hormone receptor using Escherichia coli
【24h】

Expression and purification of the extracellular domain of the human follicle-stimulating hormone receptor using Escherichia coli

机译:使用大肠杆菌表达和纯化人卵泡刺激素受体的胞外域

获取原文
获取原文并翻译 | 示例
           

摘要

Aim: Although much is known about the structure and biological functions of follicle-stimulating hormone (FSH) receptor (FSHR), the interaction of FSHR and FSH has been challenging to characterize due to the limited quantity of active FSHR protein produced by simple methods. The goal of this studywas to express and purify the extracellular domain (ECD) of human FSHR (hFSHR). Methods: Total RNA was isolated from normal human ovary tissue. cDNA for hFSHR ECD were amplified and subsequently ligated into the pET32a(+) vector. The plasmid vector construct was confirmed by polymerase chain reaction and sequencing. Expression in Escherichia coli Rosetta (DE3) pLysS strain was induced by isopropyl-thio-β-D-thiogalactoside, and the recombinant products were purified by immuno-affinity chromatography using an Ni-NTA and High-Q column. The recombinant protein was confirmed by western blotting. Results: Following induction, E. coli expressed a recombinant protein of approximately 65 kDa in size, whereas the non-induced E. coli did not express the recombinant protein. The recombinant fragments purified using a High-Q column demonstrated a single band and an abundant yield. The recombinant protein was soluble and specifically recognized by an antibody for hFSHR. Additionally, four mutation sites were detected that resulted in amino acid shifts at position 112 Asn/Thr, 197 Glu/Ala, 198 Leu/Val and 307 Ala/Thr. Conclusion: The recombinant hFSHR ECD protein was expressed and purified. This method could be easily scaled for increased production and may facilitate additional applications utilizing FSHR in assisted reproductive technology, a contraceptive FSH vaccine and FSHR-targeted therapeutic agents used to treat ovarian cancer.
机译:目的:尽管对促卵泡激素(FSH)受体(FSHR)的结构和生物学功能了解很多,但由于通过简单方法生产的活性FSHR蛋白质数量有限,FSHR和FSH的相互作用难以表征。这项研究的目的是表达和纯化人FSHR(hFSHR)的细胞外结构域(ECD)。方法:从正常人卵巢组织中分离总RNA。扩增hFSHR ECD的cDNA,然后将其连接到pET32a(+)载体中。通过聚合酶链反应和测序确认质粒载体构建体。异丙基-硫代-β-D-硫代半乳糖苷诱导在大肠杆菌Rosetta(DE3)pLysS菌株中的表达,并使用Ni-NTA和High-Q柱通过免疫亲和色谱纯化重组产物。通过蛋白质印迹证实了重组蛋白。结果:诱导后,大肠杆菌表达了大小约为65 kDa的重组蛋白,而未诱导的大肠杆菌未表达该重组蛋白。使用High-Q柱纯化的重组片段显示出一条条带和丰富的产量。重组蛋白可溶,并被hFSHR抗体特异性识别。另外,检测到四个突变位点,其导致在位置112 Asn / Thr,197 Glu / Ala,198 Leu / Val和307 Ala / Thr的氨基酸移位。结论:重组hFSHR ECD蛋白已表达并纯化。该方法可以轻松扩展规模以提高产量,并且可以促进在辅助生殖技术中使用FSHR,避孕FSH疫苗和以FSHR为靶标的治疗卵巢癌的治疗剂的其他应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号